Leejee Han Suh, MD

Closed

Photos

880 3rd Ave Ste F
New York, NY 10022
Leejee H. Suh, M.D., the Miranda Wong Tang Professor of Ophthalmology, is the Director of the Cornea Service at Columbia University's Edward S. Harkness Eye Institute. She also heads the Laser Vision Center. Her surgical specialties include femtosecond laser-assisted cataract surgery, phacoemulsification cataract surgery, LASIK (Laser Assisted In-Situ Keratomileusis), PRK (Photorefractive Keratectomy), PTK (Phototherapeutic Keratectomy), and full and partial corneal transplantation. She received her undergraduate degree from the Massachusetts Institute of Technology (M.I.T.) and her medical degree from the New York University (N.Y.U.) School of Medicine. She completed her ophthalmology residency at the Wilmer Eye Institute at the Johns Hopkins Medical Center and received her fellowship training at the Bascom Palmer Eye Institute at the University of Miami Hospitals, where she was a faculty member in the Division of Cornea and Refractive Surgery. Dr. Suh brings to Columbia her experience from the top ophthalmological institutions in the country, with an extensive background in cataract, corneal, and refractive surgery. She has authored numerous peer-reviewed articles and book chapters on corneal conditions and is active in clinical research. Her clinical research interests are in keratoconus research and treatments, namely Corneal Collagen Crosslinking. She has been the Principal Investigator for the Corneal Collagen Crosslinking trial for the treatment of keratoconus and post-refractive surgery ectasia at Columbia University. For her work in keratoconus, Dr. Suh has been named a Top Doctor for the National Keratoconus Foundation (NKCF). She was instrumental in the early studies of a newer type of partial corneal transplantation, called endothelial keratoplasty, which includes Descemet’s Stripping Automated Endothelial Keratoplasty (DSAEK) and Descemet’s Membrane Endothelial Keratoplasty (DMEK), both of which have dramatically changed the face of surgical treatments for corneal diseases. As a cornea-refractive surgeon by training, she is an expert in the latest in cataract surgery called femtosecond-laser assisted cataract surgery, in which a femtosecond laser can make precise and customized corneal and lens incisions for cataract surgery, which is combined with implantation of standard monofocal, toric, and multifocal/trifocal intraocular lens implants. With her extensive experience in corneal surgery, she is also an expert in laser vision correction and keratorefractive surgery (LASIK, PRK, and PTK). Dr. Suh has been certified by the American Board of Ophthalmology and is a fellow of the American Academy of Ophthalmology. She has presented at the annual meetings of the American Academy of Ophthalmology (AAO), Association for Research in Vision and Ophthalmology (ARVO), Asian-Pacific Association for Cataract and Refractive Surgeons (APACRS), and the American Society of Cataract and Refractive Surgery (ASCRS). She is an active reviewer for such journals as Ophthalmology, American Journal of Ophthalmology, Archives of Ophthalmology, Ocular Immunology and Inflammation, Eye, and Cornea. Dr. Suh continues to lecture nationally and internationally on her research and experience.
Click or call for more information
Owner verified
See a problem?

You might also like

Richard Evan Braunstein, MD
Internal medicine practitioners, Specialized optometrists

Richard Evan Braunstein, MD

Richard Carvajal, MD, is a leader in rare melanoma research and early phase drug development. As deputy physician-in-chief and director of medical oncology at the Northwell Health Cancer Institute, Dr. Carvajal leads all hematology and medical oncology programs across Northwell's cancer network, the largest in New York State. Dr. Carvajal is also the R. J. Zuckerberg Chair in Medical Oncology and professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell."At Northwell, we see 20,000 patients with new cancer diagnoses each year," Dr. Carvajal says. "We have this incredible opportunity and responsibility to give world-class cancer care to all of those patients. And we have the ability to do this in their backyard, so they don't have to travel." Dr. Carvajal's research is based at Northwell's Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory. He sees patients at R.J. Zuckerberg Cancer Center in Lake Success, and at Manhattan Eye, Ear & Throat Hospital. Dr. Carvajal received his medical degree from NYU Grossman School of Medicine. During his residency at the University of Michigan Medical Center, working with oncologists and cancer patients and seeing their close relationships sparked his interest in oncology. Additionally, he was excited by the progress being made in cancer treatments at the time. "A lot of the breakthroughs-targeted therapy, precision medicine, immunology-were really taking shape," he says. "The ability to develop newer and better therapies that could meaningfully benefit cancer patients really appealed to me." The desire to help develop new oncology drugs led him to complete a fellowship in medical oncology/hematology at Memorial Sloan Kettering (MSK) Cancer Center. "I wanted to take new therapies from the laboratory to the clinic and figure out which patients would be most likely to benefit from those new types of treatments," Dr. Carvajal says. Prior to joining Northwell, Dr. Carvajal led the Developmental Therapeutics Service at MSK Cancer Center. He then served as director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Irving Medical Center, as well as co-lead of the Precision Oncology and Systems Biology Program at the Herbert Irving Comprehensive Cancer Center. Dr. Carvajal has authored or co-authored more than 250 peer-reviewed articles, books, and book chapters. He serves on the editorial boards of six cancer journals. Dr. Carvajal remains excited about the ongoing breakthroughs in cancer care and the access that Northwell patients have to clinical trials. "Now is such a promising time in this field," he says. "There are new therapies being discovered, developed and approved all the time at an incredibly rapid rate. For patients with cancer, it's really important that they are seeing people who are at the forefront of this."
United StatesNew YorkNew YorkLeejee Han Suh, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.